Phase 3 N=330 Pressure Ulcer Prevention in Ventilated Patients Using Two Repositioning Regimens
Pressure Ulcers
Primary: Incidence of Pressure Ulcer (PU) Grade ≥ II — 22; 17 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=241 Evaluation of Dermal Closure With an Absorbable Barbed Suture as Compared to a Conventional Absorbable Suture
Breast Ptosis · Obesity
Primary: Total Dermal Closure Time — 12; 19.2 Minutes
Phase 3 N=1,050 Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Overall Survival — 21.5; 22.6 months — p=0.181
Phase 2 N=99 Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Parkinson Disease
Primary: Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR. — 25; 19; 19; 9 participants — p=0.1383
Phase 4 N=66 The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients
Hepatitis C, Chronic · DIABETES MELLITUS Type 2
Primary: Sustained Viral Response, — 13; 11 participants
Phase 2 N=58 A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Prostate Cancer
Primary: Testosterone Concentration in Prostate Tissue — 0.089; 0.228 Picogram per milligram (pg/mg) — p=0.0216
Phase 2 N=91 An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants
Pain · Low Back Pain · Back Pain
Primary: Change From Baseline in 11-point Numerical Rating Scale (NRS) at Week 12 — 6.9; 6.9; -3.0; -2.9 Units on a scale
Phase 3 N=391 Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)
Type 2 Diabetes Mellitus
Primary: Mean Change From Baseline in A1C at Month 6 — 8.14; 7.96; 7.90; -1.61 percent
N/A N=289 Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
Retinal Vein Occlusion · Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) 4 to 20 Weeks Following the Last OZURDEX® (Dexamethasone Intravitreal Implant) Injection — 9.8; 1.0 Lines
N/A N=23 Nonin 4 Wavelength Cerebral Oximeter Study
Healthy
Primary: Accuracy of Sensor — 5.7; 4.1 percentage saturation
Phase 4 N=96 Combination Nicotine Replacement for Alcoholic Smokers
Smoking · Alcoholism
Primary: 6 Month Smoking Abstinence — 20; 12 percentage of participants abstinent
N/A N=476 Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
HIV Infection
Primary: Number of Participants With the Frequency of Treatment Related Adverse Events. — 73; 10 participants
Phase 4 N=525 Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Smoking Cessation · Depression
Primary: Percentage of Participants With a Four-Week Continuous Quit Rate (CQR) — 35.9; 15.6 Percentage of participants — p=<0.0001
N/A N=18 Validation of Brain Oxygenation Monitor
Healthy
Primary: Accuracy of Sensor — 3.0; 8.1 percentage saturation
Phase 4 N=1,771 Antiretroviral Therapy for Advanced HIV Disease in South Africa
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants